Pharmacokinetics of taurolidine following repeated intravenous infusions measured by HPLC-ESI-MS/MS of the derivatives taurultame and taurinamide in glioblastoma patients

Clinical Pharmacokinetics

Volumn 46, Issue 6, 2007, Pages 513-524

  Stendel, Ruediger ^a   Scheurer, Louis ^b,c   Schlatterer, Kathrin ^d   Stalder, Urs ^b   Pfirrmann, Rolf W ^e   Fiss, Ingo ^a   Möhler, Hanns ^b,c   Bigler, Laurent ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c ETH ZURICH   (Switzerland)

^d UNIVERSITY OF GREIFSWALD   (Germany)

^e Charité Campus Benjamin Franklin ^*

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; TAURINAMIDE; TAUROLIDINE; TAURULTAME; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DERIVATIZATION; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GLIOBLASTOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MALE; PLASMA VOLUME; PRIORITY JOURNAL; REPEATED DRUG DOSE; REPRODUCIBILITY; TANDEM MASS SPECTROMETRY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLIC S-OXIDES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOBLASTOMA; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TAURINE; THIADIAZINES;

EID: 34249705278     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200746060-00005     Document Type: Article

References (39)

1. Knight BI, Skellern GG, Smail GA, et al. NMR studies and GC analysis of the antibacterial agent taurolidine. J Pharm Sci 1983; 72 (6): 705-7
2. Bieselt R. Surgical therapy of pleural empyema with tauroline [in German]. Langenbecks Arch Chir 1997; 382 (4 Suppl. 1): S42-6
3. Jurewitsch B, Lee T, Park J, et al. Taurolidine 2% as an antimicrobial lock solution for prevention of recurrent catheter-related bloodstream infections. J Parenter Enteral Nutr 1998; 22 (4): 242-4
4. McCartney AC, Browne MK. Clinical studies on administration of taurolidine in severe sepsis: a preliminary study. Progr Clin Biol Res 1988; 272: 361-71
5. Marti MC, Moser G, Wicki O, et al. Intravenous and intraperitoneal administration of an antiseptic: 65 cases of diffuse peritonitis treated with taurolin [in French]. Helv Chir Acta 1980; 46 (5-6): 755-8
6. Wesch G, Petermann C, Linder MM. Drug therapy of peritonitis: 6-year experience with the chemotherapeutic agent and anti-endotoxin taurolin [in German]. Fortschr Med 1983; 101 (12): 545-50
7. Browne MK. The treatment of peritonitis by an antiseptic: taurolin. Pharmatherapeutica 1981; 2 (8): 517-22
8. Browne MK, Leslie GB, Pfirrmann RW, et al. The in vitro and in vivo activity of taurolin against anaerobic pathogenic organisms. Surg Gynecol Obstet 1977; 145 (6): 842-6
9. Browne MK, Mackenzie M, Doyle PJA. A controlled trial of taurolin in established bacterial peritonitis. Surg Gynecol Obstet 1978; 146 (5): 721-4
10. Moser G, Martin MD. Forty cases of peritonitis treated without antibiotics: the intraperitoneal and intravenous use of taurolin. Praxis 1978; 67: 425-8
11. Bedrosian I, Sofia RD, Wolff SM, et al. Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine 1991; 3 (6): 568-75
12. Blenkharn JI. The antibacterial and antiendotoxin activity of taurolidine in combination with antibiotics. Surg Res Commun 1987; 2: 149-55
13. Watson RW, Redmond HP, McCarthy J, et al. Taurolidine, an antilipopolysaccharide agent, has immunoregulatory properties that are mediated by the amino acid taurine. J Leukoc Biol 1995; 58 (3): 299-306
14. Treutner KH, Bertram P, Lerch MM, et al. Prevention of postoperative adhesions by single intraperitoneal medication. J Surg Res 1995; 59 (6): 764-71
15. Leaper DJ. Prevention of peritoneal adhesions after thermal injury using noxythiolin and taurolin. In: Bruckner WL, Pfirrmann RW, editors. A new concept in antimicrobial chemotherapy for surgical infection. Baltimore: Urban and Schwarzenberg, 1985: 115-9
16. Jurewitsch B, Jeejeebhoy KN. Taurolidine lock: the key to prevention of recurrent catheter-related bloodstream infections. Clin Nutr 2005 Jun; 24 (3): 462-5
17. Calabresi P, Goulette FA, Darnowski JW. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 2001; 61 (18): 6816-21
18. Rodak R, Kubota H, Ishihara H, et al. Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. J Neurosurg 2005 Jun; 102 (6): 1055-68
19. Stendel R, Stoltenburg-Didinger G, Brock M. The aminosulphonic acid derivative taurolidine induces apoptotic changes in brain tumour cells. 12th World Congress of Neurosurgery; 2001, Sydney, 128
20. Stendel R, Stoltenburg-Didinger G, Brock M. Apoptotic changes in brain tumor cells induced by taurolidine. J Cancer Res Clin Oncol 2002; 128 Suppl. 1: 150
21. Stendel R, Stoltenburg-Didinger G, Lotte Al-Keikh C, et al. The effect of taurolidine on brain tumor cells. Anticancer Res 2002; 22 (2A): 809-14
22. Stendel R, Scheurer L, Stoltenburg-Didinger G, et al. Enhancement of Fas-ligand-mediated programmed cell death by taurolidine. Anticancer Res 2003 May-Jun;23 (3B): 2309-14
23. Stendel R, Scheurer L, Schlatterer K, et al. Taurolidine-fibrin-sealant- matrix using spray application for local treatment of brain tumors. Anticancer Res 2004 Mar-Apr;24 (2B): 631-8
24. Stendel R, Picht T, Schilling A, et al. Treatment of glioblastoma with intravenous taurolidine: first clinical experience. Anticancer Res 2004 Mar-Apr;24 (2C): 1143-7
25. McCourt M, Wang JH, Sookhai S, et al. Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol 2000; 7 (9): 685-91
26. Stendel R, Stoltenburg-Didinger G, Brock M. Taurolidine: underestimated antineoplastic effect? J Cancer Res Clin Oncol 2002; 128 Suppl. 1: 140
27. Erb F, Imbenotte M, Huvenne JP, et al. Structural investigation of a new organic antiseptic - taurolidine: analytical study and application to identification and quantitation in biological fluids. Eur J Drug Metab Pharmacokinet 1983; 8 (2): 163-73
28. Zulch KJ. Histologic typing of tumor of the central nervous system: international histological classification of tumors, No. 21. Geneva: World Health Organization, 1979
29. Knight BI, Skellern GG, Browne MK, et al. The characterisation and quantitation by high-performance liquid chromatography of the metabolites of taurolin [letter]. Br J Clin Pharmacol 1981; 12 (3): 439-40
30. Waser PG, Sibler E, Ganz AJ. Pharmakologie und toxikologie von taurolidin. In: Brückner WL, Pfirrmann RW, editors. Taurolin ein neues konzept zur antimikrobiellen chemotherapie chirurgischer infektionen. Munich: Urban and Schwarzenberg, 1985: 24-37
31. Erb F, Febvay N, Imbenotte M. Structural investigation of a new organic antiseptic - taurolidine: a spectroscopic study of its stability and equilibria in various solvents. Talanta 1982; 29: 953-8
32. Woolfson AD, Gorman SP, McCafferty DF, et al. Assay procedures for taurolin solutions using pre-column derivatisation and high-performance liquid chromatography with fluorescence detection. Int J Pharm 1989; 49: 135-40
33. Jones DS, McCafferty DF, Woolfson AD, et al. A study of the stability of taurolidine in plasma and protein-free serum. Int J Pharmaceutica 1990; 64: R1-4
34. Vankemmel M, Scherpereel P, Erb F, et al. Nouvelle approche fondamentale de la chimiothérapie anti-infectieuse en chirurgie abdominale: l'utilisation par voie locale et générale dún antiseptique - la taurolidine. In: Monographie de la Societé de Réanimation de Langue Francaise. Paris: Expansion Scientifique Francaise, 1982: 283-9
35. Notari RE. Biopharmaceutics and clinical pharmacokinetics. 4th rev. ed. New York: Marcel Dekker, 1987
36. Canal P, Gamelin E, Vassal G, et al. Benefits of pharmacological knowledge in the design and monitoring of cancer chemoment therapy. Pathol Oncol Res 1998; 4 (3): 171-8
37. Hood HT, Smail GA, Skellern GG, et al. Studies of the thiadiazine, taurolidine: identification of the molecular species present in aqueous solutions by H1 and C13-NMR spectroscopy. Talanta 1994; 1: 107-13
38. Skellern GG. Pharmacokinetics of taurolidine. In: Brückner WL, Pfirrman RW, editors. Taurolin: ein neues Konzept zur antimikrobiellen Chemotherapie chirurgischer Infektionen. Munich: Urban and Schwarzenberg, 1985: 48-50
39. Steinbach-Lebbin C, Ganz AJ, Chang A, et al. Pharmacokinetics of taurolin. Arzneimittelforschung 1982; 32 (12): 1542-6